SPOTLIGHT: Is Point finished?

Point Therapeutics is hunkering down into survival mode. The company announced it has reduced its workforce from 33 to eight and will move into temp office space is it scouts a possible sale or bankruptcy. Its lead therapy is the cancer therapy talabostat. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.